NeuroPace Inc

NPCE· Nasdaq· Surgical & Medical Instruments & Apparatus

Market cap
–
P/FCF
–
EV/Sales
–
FCF margin
-11.3%
ROIC, 5 yr avg
–
Revenue, 5 yr CAGR
+19.4%
We record prices for the companies we cover; NPCE is not one of them yet.

Company statistics

From the 10-Ks, computed in code · point at a figure for its formula

Profile · FY2025

Market cap
–
Enterprise value
–
Diluted shares
32.7M
Revenue
$100.0M
Free cash flow
-$11.3M
Owner earnings
-$22.4M

Valuation · FY2025

P/E
–
P/FCF
–
P/Owner earnings
–
EV/Sales
–
EV/FCF
–
P/B
–

Margins · FY2025

Gross
77.2%
Operating
-16.3%
Net
-21.5%
Free cash flow
-11.3%
Owner earnings
-22.4%
Stock pay
11.1%

Returns

ROIC, FY2025
–
ROIC, 5 yr avg
–
ROE, FY2025
-112.8%
ROE, 5 yr avg
-159.1%

Growth (CAGR)

Revenue, 3 yr
30.0%
Revenue, 5 yr
19.4%
Diluted EPS, 3 yr
–
Diluted EPS, 5 yr
–
Free cash flow, 3 yr
–
Free cash flow, 5 yr
–

Financial health · FY2025

Cash and investments
$61.1M
Total debt
$58.9M
Net cash
$2.2M
Debt/Equity
3.1x
Debt/FCF
–

Shareholder returns · FY2025

Dividend yield
–
Payout ratio
–
Buyback yield
–
Shareholder yield
–
Share count, 5 yr
176.1%

Financials: ten years from the 10-Ks

Reported numbers open their filing · computed ones show the formula · ˢ split-adjusted

Revenue

$100.0M

+19.4% a year over 5 years

FY2020: Revenue $41.1MFY2021: Revenue $45.2MFY2022: Revenue $45.5MFY2023: Revenue $65.4MFY2024: Revenue $79.9MFY2025: Revenue $100.0M
FY2020FY2025

Margins

Gross77.2%Operating-16.3%Net-21.5%

FY2025

FY2020: Gross 73.6%, Operating -31.7%, Net -59.0%FY2021: Gross 74.0%, Operating -52.5%, Net -79.9%FY2022: Gross 71.4%, Operating -89.6%, Net -103.4%FY2023: Gross 73.6%, Operating -41.5%, Net -50.4%FY2024: Gross 73.9%, Operating -27.1%, Net -34.0%FY2025: Gross 77.2%, Operating -16.3%, Net -21.5%
FY2020FY2025

Free cash flow and owner earnings

Free cash flow-$11.3MOwner earnings-$22.4M

FY2025

FY2020: Free cash flow -$21.7M, Owner earnings -$23.1MFY2021: Free cash flow -$25.0M, Owner earnings -$29.2MFY2022: Free cash flow -$37.5M, Owner earnings -$45.8MFY2023: Free cash flow -$19.9M, Owner earnings -$29.4MFY2024: Free cash flow -$18.3M, Owner earnings -$28.5MFY2025: Free cash flow -$11.3M, Owner earnings -$22.4M
FY2020FY2025

Diluted shares

32.7M

+15935.1% over 5 years, net dilution

FY2020: Diluted shares 204,068FY2021: Diluted shares 16.6MFY2022: Diluted shares 24.6MFY2023: Diluted shares 25.9MFY2024: Diluted shares 29.1MFY2025: Diluted shares 32.7M
FY2020FY2025

Net cash

$2.2M

$2.2M more cash than debt

FY2020: Net cash -$14.8MFY2021: Net cash $65.7MFY2022: Net cash $24.5MFY2023: Net cash $9.5MFY2024: Net cash -$6.8MFY2025: Net cash $2.2M
FY2020FY2025

Every figure, year by year

Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
The business
Revenue$41.1M$45.2M$45.5M$65.4M$79.9M$100.0M
Revenue growth–9.8%0.7%43.7%22.1%25.1%
Gross margin73.6%74.0%71.4%73.6%73.9%77.2%
Operating margin-31.7%-52.5%-89.6%-41.5%-27.1%-16.3%
Net income-$24.3M-$36.1M-$47.1M-$33.0M-$27.1M-$21.5M
Net margin-59.0%-79.9%-103.4%-50.4%-34.0%-21.5%
Diluted EPS$-117.85$-2.17$-1.91$-1.27$-0.93$-0.66
Return on invested capital?––––––
Cash
Operating cash flow-$21.6M-$24.6M-$36.9M-$19.7M-$17.9M-$11.0M
Capital expenditure$62.0K$384.0K$603.0K$173.0K$306.0K$332.0K
Free cash flow-$21.7M-$25.0M-$37.5M-$19.9M-$18.3M-$11.3M
Stock-based compensation$1.4M$4.3M$8.3M$9.6M$10.3M$11.1M
Owner earnings?-$23.1M-$29.2M-$45.8M-$29.4M-$28.5M-$22.4M
Free cash flow per share$-106.19$-1.50$-1.52$-0.77$-0.63$-0.35
Capital allocation
Dividends paid––––––
Share repurchases––––$0$49.5M
Diluted shares204,06816.6M24.6M25.9M29.1M32.7M
Share count change?–8038.9%48.1%5.1%12.7%12.3%
Balance sheet
Cash and equivalents$26.4M$19.2M$6.6M$18.1M$13.4M$21.7M
Short-term investments$11.7M$96.4M$70.8M$48.4M$39.3M$39.4M
Total debt$52.9M$49.8M$52.9M$57.0M$59.5M$58.9M
Net debt$14.8M-$65.7M-$24.5M-$9.5M$6.8M-$2.2M
Shareholders' equity-$147.8M$73.5M$34.8M$20.7M$8.0M$19.0M

Latest filings

All on EDGAR
2026-08-1110-QQuarterly report
2026-08-118-KEarnings release
2026-05-1210-QQuarterly report
2026-05-128-KEarnings release
2026-04-21DEF 14AProxy statement
2026-03-0310-KAnnual report
2026-03-038-KEarnings release
2025-11-0410-QQuarterly report
2025-11-048-KEarnings release
2025-08-1210-QQuarterly report

More from our coverage

All coverage